


**[For Immediate Release]**



## **The United Laboratories International Holdings Limited**

### **Market Launch of Acetaminophen and Dextromethorphan Hydrobromide Oral Solution - New Medicine Specializes in Treatment of Influenza and Cough**

(19 April 2009 – Hong Kong) – The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading pharmaceutical companies in the PRC, announced the official market launch of its new OTC medicine – Acetaminophen and Dextromethorphan Hydrobromide Oral Solution, which is specifically used for the treatment of symptoms caused by influenza such as fever, cough, headache, angina and muscle aches. TUL is the only manufacturer in the PRC declaring and obtaining the approval for the production of this medicine. During the monitoring period (untill 15 March 2012), other companies are not allowed to declare the production of Acetaminophen and Dextromethorphan Hydrobromide Oral Solution.

Mr. Choy Kam Lok, Chairman of TUL, said, “With the increasing health awareness, people is paying more attention nowadays to influenza which used to be an underestimated risk. The PRC government’s implementation of medical system reform with increased investment for medical expenses and enhanced medical insurance coverage for urban and rural residents also boosts the demand and sales of the medicine for influenza. The medicines specializing for treatment of influenza account for around 34% and represent the largest proportion of the OTC medicines market. Therefore, the development of OTC medicine market will drive vigorously the market growth of medicines for influenza.”

As Influenza is a common illness, the market capacity for medicines for influenza is very enormous in the PRC. According to the information from pharmacies in 30 major cities in China in 2007, the market scale for various medicines for influenza reached RMB3.22 billion, marking the breakthrough with its double-digit growth rate for two consecutive years. In 2006, the retail sales of the medicines specializing for influenza in China broke a record high with RMB10 billion. Furthermore, chemical medicines (or widely known as western medicines) accounted for 46.69% of the market for medicines for influenza in the PRC, which was higher than those of medicines combining Chinese with western prescriptions (41.36%) and Chinese medicines (11.95%). This indicated that western medicines still dominate the domestic market.

*-Cont’-*

Besides Acetaminophen and Dextromethorphan Hydrobromide Oral Solution, two new finished products of the Group, namely Imipenem cilsastatin sodium for injection and Isophane protamine human insulin injection, obtained the approval for production. They are expected to be launched this year and will drive the growth momentum of the Group.

*-End-*

**Company Background**

Listed on the Stock Exchange of Hong Kong in June 2007, **TUL** is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 31 December 2008, the Group has a total of 162 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong, including 40 bulk medicines and 122 finished products.

For further enquiries, please contact:  
iPR Ogilvy Ltd.

Sandy Yeung/ Stephanie Yuen / Tina Law / Callis Lau  
Tel: (852) 2136 8072/ 3170 6609/ 2136 6181/ 2136 6952  
Fax: (852) 3170 6606  
E-mail: sandy.yeung@iprogilvy.com/ stephanie.yuen@iprogilvy.com/  
tina.law@iprogilvy.com/ callis.lau@iprogilvy.com